Cipla Ltd.
NSE: CIPLA · Pharmaceuticals
Snapshot
Unlock Cipla Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Cipla Limited is a global pharmaceutical company that manufactures and distributes active pharmaceutical ingredients and finished formulations across diverse therapeutic areas. Its portfolio spans respiratory, cardiovascular, oncology, and infectious disease treatments, with a significant presence in India, the United States, and South Africa.
Business Model
The company generates revenue through the development, manufacturing, and commercialisation of pharmaceutical products, leveraging both proprietary formulations and strategic licensing agreements with global partners. It operates through a mix of direct sales and collaborative distribution networks to reach international markets.
- Incorporation Year:1935
Management Commentary
Management focuses on expanding the company's respiratory and biosimilar portfolios while leveraging strategic partnerships to address critical health needs. Recent efforts have prioritised the commercialisation of antiviral treatments and collaborative clinical trials to bolster the product pipeline.
Growth Outlook
Growth is expected to be driven by the expansion of the respiratory franchise, including inhalers and biosimilars, alongside the scaling of its global antiviral portfolio. Continued investment in clinical collaborations and international market penetration remains central to the company's long-term strategy.
Key Risks
- Regulatory Compliance. The company faces stringent oversight from international health authorities, where any failure to meet quality standards could lead to import bans or product recalls.
- Pricing Pressure. Increased competition and government-mandated price controls in key markets like India may compress profit margins on essential medicines.
- Intellectual Property Litigation. As a manufacturer of generic and licensed drugs, the company is susceptible to legal challenges regarding patent infringements and licensing disputes.
- Supply Chain Volatility. Dependence on global supply chains for active pharmaceutical ingredients exposes the company to geopolitical risks and raw material cost fluctuations.
Start your research today
Unlock AI insights, financials, peers and live data on Cipla Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹28,139 Cr
TTM · consolidated
NET PROFIT
₹2,854 Cr
TTM · consolidated
EPS
₹35.87
TTM · consolidated
RETURN ON EQUITY
8.4%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
11.1%
TTM · consolidated
P/E
38.7×
Q2 FY27 · consolidated
EV/EBITDA
20.0x
Q2 FY27 · consolidated
EBITDA MARGIN
19.6%
TTM · consolidated
NET PROFIT MARGIN
11.5%
Q2 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q2 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Cipla Ltd.CIPLA | ₹1.11L Cr | 38.7× | 19.98 | -0.7% | 19.6% | 8.4% | 11.1% | -7.6% |
Laurus Labs Ltd.LAURUSLABS | ₹1.30L Cr | 94.6× | 54.71 | 23.0% | 30.9% | 24.5% | 27.9% | +146.2% |
Zydus Lifesciences Ltd.ZYDUSLIFE | ₹1.24L Cr | 27.6× | 15.40 | 21.1% | 30.7% | 18.0% | 20.1% | +27.3% |
Dr. Reddy's Laboratories Ltd.DRREDDY | ₹1.13L Cr | 39.9× | 19.19 | -3.5% | 18.5% | 7.4% | 9.8% | +12.1% |
Mankind Pharma Ltd.MANKIND | ₹1.03L Cr | 45.7× | 24.36 | 13.9% | 28.6% | 13.8% | 15.0% | +4.1% |
Aurobindo Pharma Ltd.AUROPHARMA | ₹96,744 Cr | 26.3× | 12.51 | 9.1% | 22.3% | 10.5% | 15.4% | +47.8% |
As of Q2 FY27
Financials
Cipla Ltd.
NSE: CIPLA · Pharmaceuticals
Snapshot
Unlock Cipla Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Cipla Limited is a global pharmaceutical company that manufactures and distributes active pharmaceutical ingredients and finished formulations across diverse therapeutic areas. Its portfolio spans respiratory, cardiovascular, oncology, and infectious disease treatments, with a significant presence in India, the United States, and South Africa.
Business Model
The company generates revenue through the development, manufacturing, and commercialisation of pharmaceutical products, leveraging both proprietary formulations and strategic licensing agreements with global partners. It operates through a mix of direct sales and collaborative distribution networks to reach international markets.
- Incorporation Year:1935
Management Commentary
Management focuses on expanding the company's respiratory and biosimilar portfolios while leveraging strategic partnerships to address critical health needs. Recent efforts have prioritised the commercialisation of antiviral treatments and collaborative clinical trials to bolster the product pipeline.
Growth Outlook
Growth is expected to be driven by the expansion of the respiratory franchise, including inhalers and biosimilars, alongside the scaling of its global antiviral portfolio. Continued investment in clinical collaborations and international market penetration remains central to the company's long-term strategy.
Key Risks
- Regulatory Compliance. The company faces stringent oversight from international health authorities, where any failure to meet quality standards could lead to import bans or product recalls.
- Pricing Pressure. Increased competition and government-mandated price controls in key markets like India may compress profit margins on essential medicines.
- Intellectual Property Litigation. As a manufacturer of generic and licensed drugs, the company is susceptible to legal challenges regarding patent infringements and licensing disputes.
- Supply Chain Volatility. Dependence on global supply chains for active pharmaceutical ingredients exposes the company to geopolitical risks and raw material cost fluctuations.
Start your research today
Unlock AI insights, financials, peers and live data on Cipla Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹28,139 Cr
TTM · consolidated
NET PROFIT
₹2,854 Cr
TTM · consolidated
EPS
₹35.87
TTM · consolidated
RETURN ON EQUITY
8.4%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
11.1%
TTM · consolidated
P/E
38.7x
Q2 FY27 · consolidated
EV/EBITDA
20.0x
Q2 FY27 · consolidated
EBITDA MARGIN
19.6%
TTM · consolidated
NET PROFIT MARGIN
11.5%
Q2 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q2 FY27 · consolidated
Peers · Pharmaceuticals
As of Q2 FY27